The filing contains no material surprise—the widening loss was expected given Phase 3 cost ramp. The critical catalyst is the APPROACH topline data readout in Q4 2026, which will determine the program's viability. Monitor for any data release or regulatory updates. The new CEO appointment adds commercial-stage experience but does not change near-term fundamentals.
Price Chart
Executive Summary
Helus Pharma (HELP) reported Q1 FY2027 financial results with a net loss of $47.8M, widening from $24.6M in the prior-year period, driven by increased Phase 3 clinical trial costs and a $11.6M non-cash share-based compensation charge. Cash stood at $166.4M post a $50M June 2026 underwritten offering. The key operational highlight is the completion of enrollment (223 participants) in the APPROACH Phase 3 trial of HLP003 for MDD, with topline data expected in Q4 2026. The filing is a routine quarterly update with no material surprises—the widening loss is expected for a clinical-stage company advancing late-stage trials.
Key Facts
- Net loss for Q1 FY2027 was $47.8M vs. $24.6M in Q1 FY2026, largely due to a $11.6M share-based compensation charge and $30.8M in research expenses (up from $15.0M).
- Cash and cash equivalents were $166.4M as of June 30, 2026, up from $157.3M at March 31, 2026, after a $50M underwritten offering (10.3M shares at $4.85/share) closed June 25, 2026.
- Enrollment completed in the APPROACH Phase 3 trial of HLP003 for MDD on July 21, 2026 (223 participants), with topline data expected in Q4 2026.
- Michael Halstead (former President of Intra-Cellular Therapies) was appointed CEO on August 3, 2026.
- The Company has no revenue and is a pre-commercial clinical-stage biotech.
- Subsequent to quarter-end, the Company issued 7.9M shares upon RSU vesting and exercised Pre-Funded Warrants for 3.0M shares.
Financial Impact
Net loss increased 94% YoY to $47.8M; cash burn from operations was $37.1M in the quarter. Cash runway extended by $50M equity raise.
Risk Factors
- Phase 3 APPROACH trial may fail to meet primary endpoint, wiping out a significant portion of pipeline value.
- Cash burn rate ($37M/quarter operating) implies ~4.5 quarters of runway at current cash levels, requiring additional financing before topline data or shortly after.
- Highly dilutive equity structure: post-quarter-end share count increased to ~73M from ~62M at June 30 due to RSU vesting and warrant exercises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000058 |
| Document: cybin-financialstatementsx.htm | 0001833141-26-000058 |
| Document: q12027financialresultspres.htm | 0001833141-26-000058 |
| Document: cybininc-form6xkq12027.htm | 0001833141-26-000058 |
| Document: q12027-cybinceocertificate.htm | 0001833141-26-000058 |
| Document: q12027-cybincfocertificate.htm | 0001833141-26-000058 |
| Document: 0001833141-26-000058-index-headers.html | 0001833141-26-000058 |
| Document: 0001833141-26-000058-index.html | 0001833141-26-000058 |
| Document: 0001833141-26-000058.txt | 0001833141-26-000058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers